Proteome profiling to advance management of metabolic dysfunction-associated fatty liver disease

被引：0
|
作者：
Eslam, Mohammed [1 ,2 ]
Mendez-Sanchez, Nahum [3 ]
Zheng, Ming-Hua [4 ,5 ,6 ]
机构：
[1] Westmead Hosp, Westmead Inst Med Res, Storr Liver Ctr, 176 Hawkesbury Rd, Sydney, NSW 2145, Australia
[2] Univ Sydney, 176 Hawkesbury Rd, Sydney, NSW 2145, Australia
[3] Med Clin Fdn, Liver Res Unit, Mexico City, DF, Mexico
[4] Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatol, NAFLD Res Ctr, Wenzhou, Peoples R China
[5] Wenzhou Med Univ, Inst Hepatol, Wenzhou, Peoples R China
[6] Key Lab Diag & Treatment Dev Chron Liver Dis Zhej, Wenzhou, Peoples R China
来源：
HEPATOBILIARY SURGERY AND NUTRITION | 2024年 / 13卷 / 01期
基金：
英国医学研究理事会;
关键词：
Metabolic dysfunction-associated fatty liver disease (MAFLD); fatty liver disease (FLD); fibrosis; proteome; biomarkers;
D O I：
10.21037/hbsn-23-596
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：147 / 149
页数：3
相关论文
共 50 条
  • [31] Metabolic dysfunction-associated fatty liver disease in people living with HIV
    Michel, Maurice
    Labenz, Christian
    Armandi, Angelo
    Kaps, Leonard
    Kremer, Wolfgang Maximilian
    Galle, Peter R.
    Grimm, Daniel
    Sprinzl, Martin
    Schattenberg, Joern M.
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [32] Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis
    Wang, Xiaolin
    Xie, Qing
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2022, 10 (01) : 128 - 133
  • [33] Metabolic Dysfunction-Associated Fatty Liver Disease, Statins, and Atherosclerotic Cardiovascular Disease
    Chang, Hui-Chin
    Gau, Shuo-Yan
    AMERICAN JOURNAL OF MEDICINE, 2024, 137 (01): : E14 - E14
  • [34] Disease severity assessment of metabolic dysfunction-associated fatty liver disease in Taiwan
    Huang, Jee-Fu
    Tsai, Pei-Chien
    Huang, Ching-I
    Yeh, Ming-Lun
    Huang, Chung-Feng
    Dai, Chia-Yen
    Yu, Ming-Lung
    JOURNAL OF HEPATOLOGY, 2022, 77 : S458 - S459
  • [35] Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions
    Beygi, Mohammad
    Ahi, Salma
    Zolghadri, Samaneh
    Stanek, Agata
    NUTRIENTS, 2024, 16 (14)
  • [36] Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease
    Suzuki, Keito
    Tamaki, Nobuharu
    Kurosaki, Masayuki
    Takahashi, Yuka
    Yamazaki, Yudai
    Uchihara, Naoki
    Tanaka, Yuki
    Miyamoto, Haruka
    Yamada, Michiko
    Keitoku, Taisei
    Okada, Risa
    Higuchi, Mayu
    Takaura, Kenta
    Tanaka, Shohei
    Maeyashiki, Chiaki
    Yasui, Yutaka
    Tsuchiya, Kaoru
    Nakanishi, Hiroyuki
    Izumi, Namiki
    HEPATOLOGY RESEARCH, 2024, 54 (06) : 600 - 605
  • [37] Mediterranean diet affects the metabolic outcome of metabolic dysfunction-associated fatty liver disease
    Xiao, Yuji
    Zhang, Xue
    Yi, Dongxin
    Qiu, Fangyi
    Wu, Lei
    Tang, Yiyong
    Wang, Ningning
    FRONTIERS IN NUTRITION, 2023, 10
  • [38] Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
    Kani, Haluk Tarik
    Demirtas, Coskun Ozer
    Keklikkiran, Caglayan
    Ergenc, Ilkay
    Mehdiyev, Shahin
    Akdeniz, Esra
    Yilmaz, Yusuf
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2021, 32 (08): : 661 - 666
  • [39] Metabolic dysfunction-associated fatty liver disease and atherosclerotic cardiovascular disease risk: Dual aetiology or metabolic dysfunction?
    Ma, Tianyi
    Yuan, Huawei
    Guo, Zhanfang
    LIVER INTERNATIONAL, 2024, 44 (11) : 3103 - 3104
  • [40] Associations of depression score with metabolic dysfunction-associated fatty liver disease and liver fibrosis
    Cai, Hongwei
    Zhang, Rui
    Zhao, Chuanhao
    Wang, Yuzhuo
    Tu, Xiaoming
    Duan, Weiwei
    JOURNAL OF AFFECTIVE DISORDERS, 2023, 334 : 332 - 336
12345